INFLAMMOPHARMACOLOGY

Scope & Guideline

Unveiling new horizons in inflammation and therapeutic strategies.

Introduction

Welcome to the INFLAMMOPHARMACOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of INFLAMMOPHARMACOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0925-4692
PublisherSPRINGER BASEL AG
Support Open AccessNo
CountrySwitzerland
TypeJournal
Convergefrom 1991 to 2024
AbbreviationINFLAMMOPHARMACOLOGY / Inflammopharmacology
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPICASSOPLATZ 4, BASEL 4052, SWITZERLAND

Aims and Scopes

INFLAMMOPHARMACOLOGY focuses on the pharmacological aspects of inflammation and its modulation through various therapeutic agents, particularly emphasizing the mechanisms underlying anti-inflammatory actions. The journal encompasses a wide range of studies exploring both traditional and novel treatment strategies for inflammatory diseases, including but not limited to rheumatoid arthritis, neuroinflammation, and inflammatory bowel diseases.
  1. Pharmacological studies on anti-inflammatory agents:
    Research articles investigating the efficacy and safety of pharmacological agents, including traditional non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and emerging therapies like biologics and small molecules.
  2. Natural products and herbal medicine:
    Exploration of the anti-inflammatory properties of natural compounds and extracts from various plants, including traditional medicinal herbs, and their potential applications in treating inflammatory conditions.
  3. Mechanistic studies of inflammation:
    Detailed investigations into the cellular and molecular pathways involved in inflammation, including the role of cytokines, signaling pathways (such as NF-κB and NLRP3), and the immune response.
  4. Clinical trials and translational research:
    Reports on clinical trials assessing the effectiveness of new treatments for inflammatory diseases, including studies that bridge laboratory findings with clinical applications.
  5. Innovative therapeutic strategies:
    Research on novel therapies, including nanomedicine, gene therapy, and repurposing existing drugs for new indications in the context of inflammation.
The journal INFLAMMOPHARMACOLOGY is witnessing several emerging themes that reflect current scientific trends and societal needs, particularly in the context of the ongoing COVID-19 pandemic and advancements in therapeutic approaches.
  1. Research on COVID-19 and inflammatory responses:
    A significant increase in studies concerning the inflammatory responses associated with COVID-19, including the role of cytokine storms and the therapeutic potential of anti-inflammatory agents in managing COVID-19 complications.
  2. Focus on neuroinflammation and neurodegenerative diseases:
    Growing interest in the relationship between inflammation and neurodegenerative diseases like Alzheimer's and Parkinson's, with an emphasis on understanding the underlying mechanisms and exploring potential neuroprotective therapies.
  3. Exploration of gut-brain axis and inflammation:
    Emerging research on the gut-brain axis and its implications for inflammatory diseases, particularly in understanding how gut microbiota can influence systemic inflammation and neurological health.
  4. Novel therapeutic modalities and drug repurposing:
    Increased focus on innovative therapeutic strategies, including drug repurposing for inflammatory diseases, utilizing existing medications in new contexts to enhance treatment efficacy.
  5. Natural products and phytotherapy:
    A resurgence in interest towards natural products and phytochemicals for their anti-inflammatory properties, reflecting a growing trend towards integrative and holistic approaches to health.

Declining or Waning

While INFLAMMOPHARMACOLOGY continues to thrive in many areas, certain themes are showing signs of reduced emphasis in recent publications. These waning scopes suggest a shift in focus within the journal's research community.
  1. Conventional DMARDs studies:
    Research on conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) appears to be declining, possibly due to the increasing interest in biologics and targeted therapies that offer more personalized and effective treatment options for autoimmune conditions.
  2. Basic research on inflammation without therapeutic implications:
    There seems to be a waning interest in purely basic research studies that do not directly translate to therapeutic applications or clinical implications, as the journal shifts towards more clinically relevant findings.
  3. Vaccine-related inflammation studies:
    As vaccine development and research have become more established, the focus on inflammation specifically related to vaccine responses has decreased, possibly as the field matures and becomes less of a novelty.
  4. Historical perspectives and reviews:
    While historical reviews have their place, the trend indicates a decreasing number of purely historical or retrospective studies, as the journal emphasizes current research trends and forward-looking therapeutic strategies.

Similar Journals

Anti-Cancer Agents in Medicinal Chemistry

Pioneering research in medicinal chemistry for cancer treatment.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Drug Research

Advancing the Frontiers of Pharmacology
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transforming Insights into Innovations
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Journal of Inflammation Research

Leading the Way in Inflammation Research and Therapeutics
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH

Illuminating Paths in Analytical Chemistry and Beyond
Publisher: TAYLOR & FRANCIS LTDISSN: 1028-6020Frequency: 12 issues/year

JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.

JOURNAL OF EXPERIMENTAL MEDICINE

Transforming Insights into Therapeutic Strategies
Publisher: ROCKEFELLER UNIV PRESSISSN: 0022-1007Frequency: 12 issues/year

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Natural Products Journal

Advancing Knowledge in Natural Products and Therapeutics
Publisher: BENTHAM SCIENCE PUBLISSN: 2210-3155Frequency: 4 issues/year

Natural Products Journal, a leading publication by Bentham Science Publishers, primarily focuses on the rapidly evolving field of Natural Products and their applications in Complementary and Alternative Medicine as well as Drug Discovery. With an ISSN of 2210-3155 and an E-ISSN of 2210-3163, this journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the critical role of natural compounds in health and medicine. Since its inception in 2011, it has consolidated its reputation, achieving a Q3 ranking in Complementary and Alternative Medicine and a Q4 ranking in Drug Discovery as of 2023, illustrating its growing influence within the academic community. Although it currently does not operate as an Open Access journal, it remains a vital resource for cutting-edge research and developments in natural products, offering insightful contributions that pave the way for innovative therapeutic strategies. Located in the Netherlands, the journal is pivotal for those looking to stay at the forefront of research in natural substances and their multifaceted applications.

ARCHIVES OF PHARMACAL RESEARCH

Showcasing impactful discoveries in organic chemistry and beyond.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.

International Immunopharmacology

Exploring Innovative Solutions in Immunopharmacology
Publisher: ELSEVIERISSN: 1567-5769Frequency: 12 issues/year

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

Iranian Journal of Pharmaceutical Research

Championing excellence in pharmacological research and discovery.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.